Orphan drug: Difference between revisions

From DISI
Jump to navigation Jump to search
No edit summary
 
No edit summary
Line 2: Line 2:


Special rules for conducting [[clinical testing]] apply to orphan drugs that can make it faster to win approval to market.
Special rules for conducting [[clinical testing]] apply to orphan drugs that can make it faster to win approval to market.
[[Category:Jargon]]
[[Category:FDA]]

Revision as of 20:28, 20 September 2007

Orphan drugs is an FDA category that refers to medications used to treat diseases and conditions that occur rarely. There is little financial incentive for the pharmaceutical industry to develop medications for these diseases or conditions. Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications.

Special rules for conducting clinical testing apply to orphan drugs that can make it faster to win approval to market.